Business
Sierra Oncology to host call on Chk1 inhibitor
Sierra Oncology to host call on Chk1 inhibitor.
About this update from Sareum Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 0247R Sareum Holdings PLC 18 September 2017 \n\n\n\n\n\n (AIM: SAR)\n\n\n18 September 2017\n\n\n\n\nSAREUM HOLDINGS PLC\n(\"Sareum\" or \"the Company\")\nSierra Oncology to host Key Opinion Leader call with Thomas Helleday, PhD on DNA Damage Response Targets, on Tuesday 19 September\nSareum Holdings plc (AIM: SAR), the specialist cancer drug discovery and development business, notes that Sierra Oncology, the licence holder advancing clinical cancer candidate SRA737, will host a Key Opinion Leader call with Thomas Helleday, PhD on the topic of \"DNA Damage Response Targets Beyond PARP\" focusing on clinical stage DDR targets in oncology, including Checkpoint kinase 1 (Chk1), on Tuesday, September 19 at 10:30 am Eastern Time (3:30pm UK time) - details below. \nSRA737 is a potent, highly selective, orally bioavailable small molecule inhibitor of Chk1, a key regulator of important cell cycle checkpoints and central mediator of the DNA damage Response (DDR) network. Sierra Oncology holds exclusive and worldwide rights for SRA737, having licensed the programme from Sareum's co-investment partner, the CRT Pioneer Fund, in September 2016. SRA737 is currently being investigated in two Phase 1 clinical trials in patients with advanced cancer.\nThe call will feature a presentation by distinguished scientist Thomas Helleday, PhD, the Torsten and Ragnar Söderberg Professor of Translational Medicine and Chemical Biology at Karolinska Institutet, Stockholm, Sweden, who will examine emerging data and current mechanistic understandings of the next generation of clinical stage DDR targets in oncology, including Chk1. In addition, he will review which drug targets are synergistic in combination with Chk1 inhibition, and also will discuss certain preclinical DDR targets currently generating interest in the field.\nSierra Oncology's Senior Vice President of Research, Christian Hassig, PhD, will provide a brief overview on the company's research and development strategy for SRA737, which has best-in-class potential and is currently in two Phase 1 clinical trials focused on enrolling patients with tumours identified to have genetic aberrations hypothesized to confer sensitivity to Chk1 inhibition via synthetic lethality, as a monotherapy or in combination. \nThe Press release from Sierra Oncology can be found by clicking h...